新股消息 | 益方生物(688382.SH)递表港交所

智通财经01-02

智通财经APP获悉，据港交所1月1日披露，益方生物科技(上海)股份有限公司(简称：益方生物)向港交所主板递交上市申请，中信证券为其独家保荐人。招股书显示，益方生物(688382.SH)是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。截至2025年12月24日，公司已建立了全面且差异化的产品管线，包括两款商业化产品(贝福替...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2600034053?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-02 07:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2600034053","market":"sh","top_or_hot":-1,"title":"新股消息 | 益方生物(688382.SH)递表港交所","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，据港交所1月1日披露，益方生物科技(上海)股份有限公司(简称：益方生物)向港交所主板递交上市申请，中信证券为其独家保荐人。招股书显示，益方生物(688382.SH)是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。截至2025年12月24日，公司已建立了全面且差异化的产品管线，包括两款商业化产品(贝福替...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388047.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>新股消息 | 益方生物(688382.SH)递表港交所</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n新股消息 | 益方生物(688382.SH)递表港交所\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-02 07:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1388047.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，据港交所1月1日披露，益方生物科技(上海)股份有限公司(简称：益方生物)向港交所主板递交上市申请，中信证券为其独家保荐人。招股书显示，益方生物(688382.SH)是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。截至2025年12月24日，公司已建立了全面且差异化的产品管线，包括两款商业化产品(贝福替...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1388047.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1388047.html","article_id":"2600034053","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2600034053","pubTimestamp":1767311302,"columns":[{"name":"新股","id":7,"label_key":null},{"name":"递表消息","id":18,"label_key":null}],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据港交所1月1日披露，益方生物科技(上海)股份有限公司向港交所主板递交上市申请，中信证券为其独家保荐人。招股书显示，益方生物是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688382":"益方生物","BK0239":"医药制造"},"translate_title":"New Stock News | Yifang Biotech (688382. SH) submitted a form to the Hong Kong Stock Exchange","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688382":1.5,"HEXmain":1.5},"content_text":"智通财经APP获悉，据港交所1月1日披露，益方生物科技(上海)股份有限公司(简称：益方生物)向港交所主板递交上市申请，中信证券为其独家保荐人。招股书显示，益方生物(688382.SH)是一家立足中国、布局全球的研发驱动型生物制药公司，专注于肿瘤、自身免疫性疾病及代谢性疾病等存在大量未被满足需求的重大疾病领域。截至2025年12月24日，公司已建立了全面且差异化的产品管线，包括两款商业化产品(贝福替尼(BPI-D0316)及格索雷塞(D 1553))、两款临床阶段核心产品(D-2570及泰瑞司群(D-0502))、一款临床阶段候选产品(达比诺雷(D-0120))及三个临床前候选产品(YF087、YF550及YF057)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2600034053","isCrawlerRequest":true}